Joshua B Brown1, Mitchell J Cohen, Joseph P Minei, Ronald V Maier, Michaela A West, Timothy R Billiar, Andrew B Peitzman, Ernest E Moore, Joseph Cuschieri, Jason L Sperry. 1. *Division of General Surgery and Trauma, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA †Department of Surgery, University of California, San Francisco, CA ‡Division of Burn, Trauma, Critical Care, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX §Division of General Surgery and Trauma, Harborview Medical Center, and the Department of Surgery, University of Washington, Seattle, WA; and ‖Department of Surgery, Denver Health Medical Center, and The University of Colorado Health Sciences Center, Denver, CO.
Abstract
OBJECTIVE: To evaluate the association of pretrauma center (PTC) red blood cell (RBC) transfusion with outcomes in severely injured patients. BACKGROUND: Hemorrhage remains a major driver of mortality. Little evidence exists supporting PTC interventions to mitigate this. METHODS: Blunt injured patients in shock arriving at a trauma center within 2 hours of injury were included from the Glue Grant database. Subjects were dichotomized by PTC RBC transfusion. Outcomes included 24-hour mortality, 30-day mortality, and trauma-induced coagulopathy [(TIC), admission international normalized ratio >1.5]. Cox regression and logistic regression determined the association of PTC RBC transfusion with outcomes. To address baseline differences, propensity score matching was used. RESULTS: Of 1415 subjects, 50 received PTC RBC transfusion. Demographics and injury severity score were similar. The PTC RBC group received 1.3 units of RBCs (median), and 52% were scene transports. PTC RBC transfusion was associated with a 95% reduction in odds of 24-hour mortality [odds ratio (OR) = 0.05; 95% confidence interval (CI), 0.01-0.48; P < 0.01], 64% reduction in the risk of 30-day mortality [hazard ratio = 0.36; 95% CI, 0.15-0.83; P = 0.02], and 88% reduction in odds of TIC (OR = 0.12; 95% CI, 0.02-0.79; P = 0.03). The matched cohort included 113 subjects (31% PTC RBC group). Baseline characteristics were similar. PTC RBC transfusion was associated with a 98% reduction in odds of 24-hour mortality (OR = 0.02; 95% CI, 0.01-0.69; P = 0.04), 88% reduction in the risk of 30-day mortality (hazard ratio = 0.12; 95% CI, 0.03-0.61; P = 0.01), and 99% reduction in odds of TIC (OR = 0.01; 95% CI, 0.01-0.95; P = 0.05). CONCLUSIONS: PTC RBC administration was associated with a lower risk of 24-hour mortality, 30-day mortality, and TIC in severely injured patients with blunt trauma, warranting further prospective study.
OBJECTIVE: To evaluate the association of pretrauma center (PTC) red blood cell (RBC) transfusion with outcomes in severely injured patients. BACKGROUND:Hemorrhage remains a major driver of mortality. Little evidence exists supporting PTC interventions to mitigate this. METHODS: Blunt injured patients in shock arriving at a trauma center within 2 hours of injury were included from the Glue Grant database. Subjects were dichotomized by PTC RBC transfusion. Outcomes included 24-hour mortality, 30-day mortality, and trauma-induced coagulopathy [(TIC), admission international normalized ratio >1.5]. Cox regression and logistic regression determined the association of PTC RBC transfusion with outcomes. To address baseline differences, propensity score matching was used. RESULTS: Of 1415 subjects, 50 received PTC RBC transfusion. Demographics and injury severity score were similar. The PTC RBC group received 1.3 units of RBCs (median), and 52% were scene transports. PTC RBC transfusion was associated with a 95% reduction in odds of 24-hour mortality [odds ratio (OR) = 0.05; 95% confidence interval (CI), 0.01-0.48; P < 0.01], 64% reduction in the risk of 30-day mortality [hazard ratio = 0.36; 95% CI, 0.15-0.83; P = 0.02], and 88% reduction in odds of TIC (OR = 0.12; 95% CI, 0.02-0.79; P = 0.03). The matched cohort included 113 subjects (31% PTC RBC group). Baseline characteristics were similar. PTC RBC transfusion was associated with a 98% reduction in odds of 24-hour mortality (OR = 0.02; 95% CI, 0.01-0.69; P = 0.04), 88% reduction in the risk of 30-day mortality (hazard ratio = 0.12; 95% CI, 0.03-0.61; P = 0.01), and 99% reduction in odds of TIC (OR = 0.01; 95% CI, 0.01-0.95; P = 0.05). CONCLUSIONS:PTC RBC administration was associated with a lower risk of 24-hour mortality, 30-day mortality, and TIC in severely injured patients with blunt trauma, warranting further prospective study.
Authors: Robert F Malsby; Jose Quesada; Nicole Powell-Dunford; Ren Kinoshita; John Kurtz; William Gehlen; Colleen Adams; Dustin Martin; Stacy Shackelford Journal: Mil Med Date: 2013-07 Impact factor: 1.437
Authors: Elon Glassberg; Roy Nadler; Sami Gendler; Amir Abramovich; Philip C Spinella; Robert T Gerhardt; John B Holcomb; Yitshak Kreiss Journal: Shock Date: 2013-12 Impact factor: 3.454
Authors: Ernest E Moore; Theresa L Chin; Michael C Chapman; Eduardo Gonzalez; Hunter B Moore; Christopher C Silliman; Kirk C Hansen; Angela Sauaia; Anirban Banerjee Journal: Shock Date: 2014-05 Impact factor: 3.454
Authors: Elaheh Rahbar; Erin E Fox; Deborah J del Junco; John A Harvin; John B Holcomb; Charles E Wade; Martin A Schreiber; Mohammad H Rahbar; Eileen M Bulger; Herb A Phelan; Karen J Brasel; Louis H Alarcon; John G Myers; Mitchell J Cohen; Peter Muskat; Bryan A Cotton Journal: J Trauma Acute Care Surg Date: 2013-07 Impact factor: 3.313
Authors: David A Hampton; Löic J Fabricant; Jerry Differding; Brian Diggs; Samantha Underwood; Dodie De La Cruz; John B Holcomb; Karen J Brasel; Mitchell J Cohen; Erin E Fox; Louis H Alarcon; Mohammad H Rahbar; Herb A Phelan; Eileen M Bulger; Peter Muskat; John G Myers; Deborah J del Junco; Charles E Wade; Bryan A Cotton; Martin A Schreiber Journal: J Trauma Acute Care Surg Date: 2013-07 Impact factor: 3.313
Authors: Donald Jenkins; James Stubbs; Steve Williams; Kathleen Berns; Martin Zielinski; Geir Strandenes; Scott Zietlow Journal: Shock Date: 2014-05 Impact factor: 3.454
Authors: Joshua B Brown; Jason L Sperry; Anisleidy Fombona; Timothy R Billiar; Andrew B Peitzman; Francis X Guyette Journal: J Am Coll Surg Date: 2015-01-24 Impact factor: 6.113
Authors: Anthony E Pusateri; Ernest E Moore; Hunter B Moore; Tuan D Le; Francis X Guyette; Michael P Chapman; Angela Sauaia; Arsen Ghasabyan; James Chandler; Kevin McVaney; Joshua B Brown; Brian J Daley; Richard S Miller; Brian G Harbrecht; Jeffrey A Claridge; Herb A Phelan; William R Witham; A Tyler Putnam; Jason L Sperry Journal: JAMA Surg Date: 2020-02-19 Impact factor: 14.766
Authors: John B Holcomb; Michael D Swartz; Stacia M DeSantis; Thomas J Greene; Erin E Fox; Deborah M Stein; Eileen M Bulger; Jeffrey D Kerby; Michael Goodman; Martin A Schreiber; Martin D Zielinski; Terence O'Keeffe; Kenji Inaba; Jeffrey S Tomasek; Jeanette M Podbielski; Savitri N Appana; Misung Yi; Charles E Wade Journal: J Trauma Acute Care Surg Date: 2017-07 Impact factor: 3.313
Authors: Clemens Boecker; Nicole Sitzmann; Jose Luis Halblaub Miranda; Hajo Suhr; Philipp Wiedemann; Karen Bieback; Marcus Rudolph; Harald Klüter Journal: Transfus Med Hemother Date: 2022-02-15 Impact factor: 4.040
Authors: Husayn A Ladhani; Vanessa P Ho; C Clare Charbonnet; Jason L Sperry; Francis X Guyette; Joshua B Brown; Brian J Daley; Richard S Miller; Brian G Harbrecht; Herb A Phelan; Jeffrey A Claridge Journal: J Trauma Acute Care Surg Date: 2021-08-01 Impact factor: 3.697
Authors: Joshua B Brown; Christine M Leeper; Jason L Sperry; Andrew B Peitzman; Timothy R Billiar; Barbara A Gaines; Mark L Gestring Journal: J Trauma Acute Care Surg Date: 2016-05 Impact factor: 3.313
Authors: Katherine M Reitz; Hunter B Moore; Frank X Guyette; Angela Sauaia; Anthony E Pusateri; Ernest E Moore; Adnan Hassoune; Michael P Chapman; Brian J Daley; Richard S Miller; Brian G Harbrecht; Jeffrey A Claridge; Herb A Phelan; Joshua B Brown; Brian S Zuckerbraun; Matthew D Neal; Mark H Yazer; Jason L Sperry Journal: J Trauma Acute Care Surg Date: 2020-01 Impact factor: 3.697